Celyad Oncology Sa (CYAD) SEC Filing 6-K Foreign Issuer Report for the period ending Wednesday, December 8, 2021

Celyad S.A.

CIK: 1637890 Ticker: CYAD

View differences made from one to another to evaluate Celyad S.A.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Celyad S.A..


Assess how Celyad S.A.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Celyad S.A.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Celyad S.A. provided additional information to their SEC Filing as exhibits

Ticker: CYAD
CIK: 1637890
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001193125-21-351445
Submitted to the SEC: Wed Dec 08 2021 4:27:30 PM EST
Accepted by the SEC: Wed Dec 08 2021
Period: Wednesday, December 8, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: